Status:
COMPLETED
Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With Temozolomide
Lead Sponsor:
Washington University School of Medicine
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
This clinical trial studies disulfiram in treating patients with glioblastoma multiforme (GBM) who have completed radiation therapy with temozolomide. Disulfiram may block some of the enzymes needed f...
Eligibility Criteria
Inclusion
- Diagnosis of histologically confirmed GBM (WHO grade IV).
- At least 18 years of age.
- ECOG performance status of at least 2.
- Has received or is in the process of completing a course of definitive radiotherapy of at least 45 Gy with concurrent temozolomide (patient may be registered before completing radiotherapy as long as it is anticipated that s/he will complete at least 45 Gy).
- Eligible for and planning to receive maintenance temozolomide after completion of definitive radiotherapy plus temozolomide.
- Willing to remain abstinent from consuming alcohol while on disulfiram.
- Meets the following laboratory criteria:
- Absolute neutrophil count ≥ 1,500/mcL
- Platelets ≥ 100,000/mcL
- Hemoglobin \> 9.0 g/dL (transfusion and/or ESA allowed)
- Total bilirubin ≤ 2x institutional upper limit of normal (ULN)
- AST and ALT \< 3 x ULN
- Calculated creatinine clearance must be \> 60 mL/min (by Cockcroft-Gault)
- Females of childbearing potential (defined as a female who is non-menopausal or surgically sterilized) must be willing to use an acceptable method of birth control (i.e., hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately.
- Able to take oral medication.
- Able to understand and willing to sign an IRB-approved written informed consent document (legally authorized representative permitted).
Exclusion
- Receipt of any other investigational agents within 14 days prior to study enrollment.
- Enrolled on another clinical trial testing a novel therapy or drug.
- History of allergic reaction to disulfiram.
- Treatment with clinically significant cytochromes P450 enzyme inducers, such as phenytoin, phenobarbital, chlordiazepoxide, diazepam, isoniazid, metronidazole, warfarin, amitriptyline within 14 days prior to the first dose of disulfiram. Of note, lorazepam and oxazepam are not affected by the P450 system and are not contraindicated with disulfiram.
- Active or severe hepatic, cardiovascular, or cerebrovascular disease, including myocardial infarction within 6 months prior to enrollment, have New York Heart Association (NYHA) Class III or IV heart failure (Appendix B), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
- History of idiopathic seizure disorder, psychosis or schizophrenia.
- Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of initiation of treatment.
Key Trial Info
Start Date :
October 10 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 9 2018
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT01907165
Start Date
October 10 2013
End Date
February 9 2018
Last Update
July 20 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Washington University School of Medicine
St Louis, Missouri, United States, 63110